<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784535</url>
  </required_header>
  <id_info>
    <org_study_id>160415</org_study_id>
    <nct_id>NCT02784535</nct_id>
  </id_info>
  <brief_title>Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)</brief_title>
  <acronym>NETAF</acronym>
  <official_title>Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug therapy for patients suffering from autonomic failure and neurogenic orthostatic
      hypotension are scarce and not effective. If left untreated, these patients have the highest
      risk of syncope, falls and fall-related injuries. The proposed study will determine the
      clinical benefit of a commercially available drug, atomoxetine, to reduce symptoms associated
      with neurogenic orthostatic hypotension in patients with autonomic failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autonomic failure is a group of rare neurodegenerative disorders that primarily affect the
      autonomic nervous system. These patients develop neurogenic orthostatic hypotension (OH)
      because of impaired autonomic reflexes that control cardiovascular and neuro-humoral
      adaptation to upright posture. The treatment of neurogenic OH is challenging; the therapeutic
      options are scarce, and some patients are refractory to treatment.

      Atomoxetine is a selective norepinephrine transporter inhibitor that increases the
      availability of norepinephrine in the synapse by blocking its reuptake. Our preliminary data
      in sixty-five patients with primary autonomic failure and neurogenic OH showed that
      atomoxetine was more effective than midodrine, standard of care, in improving standing SBP
      (+7.5 mm Hg). Notably, only atomoxetine and not midodrine induced a significant reduction in
      OH-related symptoms (lightheadedness and dizziness) compared with placebo. In this proposal,
      we will test the hypothesis that prolonged administration of the norepinephrine transporter
      blocker, atomoxetine, improves OH-related symptoms and OH-impact on daily activities compared
      with placebo in autonomic failure patients. We propose a randomized, double-blind,
      placebo-controlled, 2x2 crossover study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 29, 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Orthostatic Hypotension Questionnaire</measure>
    <time_frame>2 weeks</time_frame>
    <description>Questionnaire that assess pre-syncopal symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 weeks</time_frame>
    <description>blood pressure assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neurogenic Orthostatic Hypotension</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atomoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atomoxetine capsules 10 mg or 18 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>norepinephrine transporter inhibitor</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>atomoxetine</arm_group_label>
    <other_name>non active medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40 years old or older

          -  Neurogenic Orthostatic Hypotension (defined by a reduction of ≥20 mmHg drop in SBP
             within 3 minutes of standing, associated with impaired autonomic reflexes as assessed
             by autonomic function tests.

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Hypersensitivity to atomoxetine (severe allergic reaction, rash, urticaria,
             anaphylaxis)

          -  Use of other norepinephrine transporter inhibitors such as Wellbutrin (Bupropion),
             Cymbalta (Duloxetine), Effexor (venlafaxine), Pristiq (desvenlafaxine), Savella
             (milnacipran)

          -  Previous history (within 14 days prior to enrollment) and current use of monoamine
             oxidase inhibitors

          -  Concomitant use of strong CYP2D6 inhibitors such as delavirdine, paroxetine,
             fluoxetine, quinidine

          -  Pre-existing sustained severe hypertension (BP ≥ 140/80 mmhg in the sitting position)

          -  Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino
             transaminase [ALT] &gt;2 x upper limit of normal range)

          -  Impaired renal function (serum creatinine equal or more than 1.6 mg/dl)

          -  Myocardial infarction within 6 months prior to enrollment

          -  Congestive heart failure (LV hypertrophy acceptable)

          -  History of serious neurologic disease such as cerebral hemorrhage, or stroke

          -  Inability to comply with the protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, unlikelihood of completing the study, and mental
             conditions rendering the subject unable to understand the nature, scope, and possible
             consequences of the study

          -  Narrow-angle glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyndya A Shibao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Horacio Kaufmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dysautonomic Center at NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, Raj SR, Robertson D, Biaggioni I, Shibao CA. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014 Dec;64(6):1235-40. doi: 10.1161/HYPERTENSIONAHA.114.04225. Epub 2014 Sep 2.</citation>
    <PMID>25185131</PMID>
  </reference>
  <reference>
    <citation>Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, Robertson D, Biaggioni I. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007 Jul;50(1):47-53. Epub 2007 May 21.</citation>
    <PMID>17515448</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Cyndya Shibao</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>norepinephrine transporter inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

